Citation Impact
Citing Papers
Oxidative Stress
2017 Standout
Predicting Survival in Pulmonary Arterial Hypertension
2010 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
2019 StandoutNobel
Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey
2009
Abdominal obesity and metabolic syndrome
2006 StandoutNature
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
2015
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
2015
Global estimates of diabetes prevalence for 2013 and projections for 2035
2013 Standout
The metabolic syndrome
2010 Standout
Regional variations in cardiovascular risk factors in India: India heart watch
2012
Exercise Standards for Testing and Training
2013 Standout
Redox regulation of antioxidants, autophagy, and the response to stress: Implications for electrophile therapeutics
2014
The changing landscape of atherosclerosis
2021 StandoutNature
Clinical Impact of Metabolic Syndrome and Its Additive Effect With Smoking on Subsequent Cardiac Events After Acute Myocardial Infarction
2007
Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries
2013 Standout
Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients
2008
Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: A randomized, controlled study
2014
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases
2009 Standout
Comprehensive Approach for Hypertension Control in Low-Income Populations: Rationale and Study Design for the Hypertension Control Program in Argentina
2014
Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials
2018
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
The Metabolic Syndrome and Cardiovascular Risk
2010 Standout
Prevention of Heart Failure
2008
Bladder cancer
2016 Standout
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
2018 Standout
Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy
2013 Standout
Global Secondary Prevention Strategies to Limit Event Recurrence After Myocardial Infarction
2008
Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension
2011
Clinician’s Guide to Cardiopulmonary Exercise Testing in Adults
2010 Standout
Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension
2009 StandoutNobel
The Metabolic Basis of Pulmonary Arterial Hypertension
2014
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
2008
Impact of the Metabolic Syndrome on the Clinical Outcomes of Non-Clinically Diagnosed Diabetic Patients With Acute Coronary Syndrome
2007
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention
2011
Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department
2010
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
2015 Standout
Hypertension prevalence, awareness, treatment and control among older people in Latin America, India and China
2011
The increase in pulmonary arterial pressure caused by hypoxia depends on iron status
2008 StandoutNobel
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study
2007
Omega-3 Fatty Acids and Cardiovascular Disease
2011
Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis
2013 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland
2009
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Metabolic Syndrome and Incident Diabetes
2008
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes
2010
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Pulmonary Arterial Hypertension
2006
Global Disparities of Hypertension Prevalence and Control
2016 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2018 Standout
Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association
2016
High-Calorie-Expenditure Exercise
2009
Worldwide Epidemiology of Atrial Fibrillation
2013 Standout
Interventions for enhancing medication adherence
2014 Standout
Fish Oil and Post-Operative Atrial Fibrillation
2013
Geometry of the Randomized Evidence for Treatments of Pulmonary Hypertension
2013
Metabolic Syndrome Predicts 10-Year Mortality in Non-Diabetic Patients Following Coronary Artery Bypass Surgery
2008
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Diagnosis and Treatment of Secondary (Non–Category 1) Pulmonary Hypertension
2008
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
2008
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
2013 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Cardiovascular Diseases in India
2016 Standout
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Medication Adherence
2009 Standout
Works of Alejandro Macchia being referenced
CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities
2008
A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology
2007
Fish Oil and Postoperative Atrial Fibrillation
2012
Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial
2005
Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed
2010
The ω-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trial—rationale and design
2011
Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation
2012
Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction
2005
Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction
2008
A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)–Prevenzione scoring
2006
Long-Term Results After a Telephone Intervention in Chronic Heart Failure
2010
High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study
2009
The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure
2007
Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n‐3 polyunsaturated fatty acids
2005
Plasma Phospholipid Omega‐3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial
2013
N‐3 Polyunsaturated Fatty Acids to Prevent Atrial Fibrillation: Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials
2013
Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial
2006